Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Therapeutic Human Papillomavirus (HPV) Vaccines: A Novel Approach.

Kawana K, Adachi K, Kojima S, Kozuma S, Fujii T.

Open Virol J. 2012;6:264-9. doi: 10.2174/1874357901206010264. Epub 2012 Dec 28.

2.

Therapeutic human papillomavirus vaccines: current clinical trials and future directions.

Hung CF, Ma B, Monie A, Tsen SW, Wu TC.

Expert Opin Biol Ther. 2008 Apr;8(4):421-39. doi: 10.1517/14712598.8.4.421 . Review.

3.

Human papillomavirus vaccines: current issues & future.

Kawana K, Yasugi T, Taketani Y.

Indian J Med Res. 2009 Sep;130(3):341-7. Review.

PMID:
19901444
4.

The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.

Brinkman JA, Caffrey AS, Muderspach LI, Roman LD, Kast WM.

Eur J Gynaecol Oncol. 2005;26(2):129-42. Review.

PMID:
15857016
5.

Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients.

Kawana K, Adachi K, Kojima S, Taguchi A, Tomio K, Yamashita A, Nishida H, Nagasaka K, Arimoto T, Yokoyama T, Wada-Hiraike O, Oda K, Sewaki T, Osuga Y, Fujii T.

Vaccine. 2014 Oct 29;32(47):6233-9. doi: 10.1016/j.vaccine.2014.09.020. Epub 2014 Sep 22.

PMID:
25258102
6.

[Cervical cancer prevention: the impact of HPV vaccination].

Monsonégo J.

Gynecol Obstet Fertil. 2006 Mar;34(3):189-201. Epub 2006 Mar 10. Review. French.

PMID:
16529969
8.

Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

J Virol. 2009 Jul;83(13):6779-89. doi: 10.1128/JVI.02443-08. Epub 2009 Apr 22.

9.

Chapter 16: Prophylactic human papillomavirus vaccines.

Lowy DR, Frazer IH.

J Natl Cancer Inst Monogr. 2003;(31):111-6. Review.

PMID:
12807954
10.

Primary prevention of cervical cancer: prophylactic human papillomavirus vaccines.

Mandic A.

J BUON. 2012 Jul-Sep;17(3):422-7. Review.

PMID:
23033276
11.

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.

Rambout L, Hopkins L, Hutton B, Fergusson D.

CMAJ. 2007 Aug 28;177(5):469-79. Epub 2007 Aug 1. Review.

12.

Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer.

Monie A, Hung CF, Roden R, Wu TC.

Biologics. 2008 Mar;2(1):97-105.

13.

[Toward cervical cancer prevention: strategies employed in the development of HPV vaccines].

de la Cruz-Hernández E, Contreras-Paredes A, Lizano-Soberón M.

Rev Invest Clin. 2006 Nov-Dec;58(6):586-97. Review. Spanish.

PMID:
17432291
14.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

PMID:
20139221
15.

[Human papillomavirus prophylactic vaccines: stakes and perspectives].

Hantz S, Alain S, Denis F.

Gynecol Obstet Fertil. 2006 Jul-Aug;34(7-8):647-55. Epub 2006 Jun 27. Review. French.

PMID:
16807045
16.

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.

Hallez S, Simon P, Maudoux F, Doyen J, Noël JC, Beliard A, Capelle X, Buxant F, Fayt I, Lagrost AC, Hubert P, Gerday C, Burny A, Boniver J, Foidart JM, Delvenne P, Jacobs N.

Cancer Immunol Immunother. 2004 Jul;53(7):642-50. Epub 2004 Feb 17.

17.

Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.

Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E.

Obstet Gynecol. 2006 Jan;107(1):18-27. Erratum in: Obstet Gynecol. 2006 Jun;107(6):1425.

PMID:
16394035
18.

Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.

Van Kriekinge G, Castellsagué X, Cibula D, Demarteau N.

Vaccine. 2014 Feb 3;32(6):733-9. doi: 10.1016/j.vaccine.2013.11.049. Epub 2013 Nov 26.

19.

Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).

Kaufmann AM, Nieland JD, Jochmus I, Baur S, Friese K, Gabelsberger J, Gieseking F, Gissmann L, Glasschröder B, Grubert T, Hillemanns P, Höpfl R, Ikenberg H, Schwarz J, Karrasch M, Knoll A, Küppers V, Lechmann M, Lelle RJ, Meissner H, Müller RT, Pawlita M, Petry KU, Pilch H, Walek E, Schneider A.

Int J Cancer. 2007 Dec 15;121(12):2794-800.

20.

Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection.

Asiaf A, Ahmad ST, Mohammad SO, Zargar MA.

Eur J Cancer Prev. 2014 May;23(3):206-24. doi: 10.1097/CEJ.0b013e328364f273. Review.

PMID:
24129107

Supplemental Content

Support Center